Vertex Pharmaceuticals Inc (NASDAQ:VRTX)

350.03

Delayed Data

As of Dec 08

-3.92 / -1.11%

Today’s Change

282.21

Today|||52-Week Range

387.42

+21.21%

Year-to-Date

Latest VRTX News | Press Releases

3 Unstoppable Stocks to Buy Right Now 6:56am / MotleyFool.com - Paid Partner Content	A Bull Market Is Coming. Here Are 3 Stocks You'll Absolutely Want to Own. Dec 04 / MotleyFool.com - Paid Partner Content
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy? 5:45am / MotleyFool.com - Paid Partner Content	Where Will Vertex Pharmaceuticals Be in 10 Years? Dec 04 / MotleyFool.com - Paid Partner Content
Forget the "Magnificent Seven": Buy This Stock Instead Dec 09 / MotleyFool.com - Paid Partner Content	3 No-Brainer Growth Stocks to Buy in December Dec 03 / MotleyFool.com - Paid Partner Content
2 Superior Growth Stocks Up 23% and 105% in 2023 to Buy Now and Hold for Years Dec 09 / MotleyFool.com - Paid Partner Content	Got $5,000? These Are 2 of the Best Growth Stocks to Buy Right Now Dec 03 / MotleyFool.com - Paid Partner Content
CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried? Dec 08 / MotleyFool.com - Paid Partner Content	5 Top Stocks to Buy Before 2024 Dec 02 / MotleyFool.com - Paid Partner Content
This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics Dec 07 / MotleyFool.com - Paid Partner Content	Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now? Dec 01 / Zacks.com - Paid Partner Content
5 Unstoppable Trends to Invest $1,000 in for 2024 Dec 07 / MotleyFool.com - Paid Partner Content	Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? Dec 01 / MotleyFool.com - Paid Partner Content
Why Is Vertex (VRTX) Down 6.4% Since Last Earnings Report? Dec 06 / Zacks.com - Paid Partner Content	Looking for Growth? 2 Top Stocks to Buy Hand Over Fist Dec 01 / MotleyFool.com - Paid Partner Content
CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline Dec 05 / Zacks.com - Paid Partner Content	The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie Dec 01 / Zacks.com - Paid Partner Content
Better Growth Stock: CRISPR Therapeutics vs. Invitae Dec 05 / MotleyFool.com - Paid Partner Content	Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More Nov 30 / Zacks.com - Paid Partner Content
GSK vs. VRTX: Which Stock Should Value Investors Buy Now? Dec 04 / Zacks.com - Paid Partner Content	Arcturus' (ARCT) CF Drug Gets FDA's Orphan Status, Stock Up Nov 28 / Zacks.com - Paid Partner Content
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. Dec 04 / MotleyFool.com - Paid Partner Content